These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis. Reischig T, Jindra P, Hes O, Bouda M, Kormunda S, Treska V. Transplantation; 2009 Feb 15; 87(3):436-44. PubMed ID: 19202451 [Abstract] [Full Text] [Related]
9. A randomized prospective trial of oral versus intravenous ganciclovir for prophylaxis of cytomegalovirus infection and disease in high-risk kidney recipients. Nafar M, Pezeshki ML, Farrokhi F, Einollahi B, Pour-Reza-Gholi F, Firouzan A, Farhangi S. Transplant Proc; 2005 Sep 15; 37(7):3053-5. PubMed ID: 16213302 [Abstract] [Full Text] [Related]
10. Comparative analysis of azathioprine versus cyclosporine-based therapy in primary haplo-identical live-donor kidney transplantation: a 20-year experience. Gheith OA, Bakr MA, Fouda MA, Shokeir AA, Sobh M, Ghoneim M. Saudi J Kidney Dis Transpl; 2008 Jul 15; 19(4):564-70. PubMed ID: 18580014 [Abstract] [Full Text] [Related]
11. Cytomegalovirus infection in seronegative patients treated with prophylaxis: case-controlled study. Moreno de la Higuera Díaz MA, Calvo Romero N, Sánchez-Fructuoso A, Conesa J, Marques Vidas M, Prats D, Barrientos Guzmán A. Transplant Proc; 2007 Sep 15; 39(7):2231-2. PubMed ID: 17889147 [Abstract] [Full Text] [Related]
12. Cytomegalovirus disease in renal transplant recipients: an Iranian experience. Nemati E, Taheri S, Pourfarziani V, Einollahi B. Exp Clin Transplant; 2008 Jun 15; 6(2):132-6. PubMed ID: 18816240 [Abstract] [Full Text] [Related]
14. Cytomegalovirus infection in kidney transplant recipients: Evolution of approach through three eras. Boucher A, Lord H, Collette S, Morin M, Dandavino R. Transplant Proc; 2006 Dec 15; 38(10):3506-8. PubMed ID: 17175316 [Abstract] [Full Text] [Related]
15. Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation. Slifkin M, Ruthazer R, Freeman R, Bloom J, Fitzmaurice S, Fairchild R, Angelis M, Cooper J, Barefoot L, Rohrer R, Snydman DR. Liver Transpl; 2005 Dec 15; 11(12):1597-602. PubMed ID: 16315314 [Abstract] [Full Text] [Related]
16. Preemptive kidney transplant from deceased donors: an advantage in relation to reduced waiting list. Pérez-Flores I, Sánchez-Fructuoso A, Calvo N, Marques M, Anaya S, Ridao N, Rodríguez A, Barrientos A. Transplant Proc; 2007 Sep 15; 39(7):2123-4. PubMed ID: 17889112 [Abstract] [Full Text] [Related]
17. The emergence of cytomegalovirus resistance to ganciclovir therapy in kidney transplant recipients. Nogueira E, Ozaki KS, Tomiyama H, Granato CF, Camara NO, Pacheco-Silva A. Int Immunopharmacol; 2006 Dec 20; 6(13-14):2031-7. PubMed ID: 17161359 [Abstract] [Full Text] [Related]
18. Infectious complications after deceased kidney donor transplantation. Guimarães-Souza NK, Dalboni MA, Câmara NC, Medina-Pestana JO, Paheco-Silva A, Cendoroglo M. Transplant Proc; 2010 May 20; 42(4):1137-41. PubMed ID: 20534244 [Abstract] [Full Text] [Related]
19. Delayed graft function in renal transplant recipients: risk factors and impact on 1-year graft function: a single center analysis. Bronzatto EJ, da Silva Quadros KR, Santos RL, Alves-Filho G, Mazzali M. Transplant Proc; 2009 Apr 20; 41(3):849-51. PubMed ID: 19376369 [Abstract] [Full Text] [Related]
20. Kidney graft survival in patients with hepatitis C: a single center experience. Arango J, Arbelaez M, Henao J, Mejia G, Arroyave I, Carvajal J, Garcia A, Gutierrez J, Velásquez A, Garcia L, Aguirre C. Clin Transplant; 2008 Apr 20; 22(1):16-9. PubMed ID: 18217900 [Abstract] [Full Text] [Related] Page: [Next] [New Search]